Inflammation and chronic inflammation
Education on Inflammation and chronic inflammation and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Inflammation and chronic inflammation and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Inflammation and chronic inflammation?
Inflammation and chronic inflammation is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Chronic inflammation can affect many parts of the body over time.
What Mark Egly's patent discusses
Inflammation is a vital part of the immune system's response to injury and infection. Inflammation signals the immune system to heal and repair damaged tissue and defend the body against foreign invaders, such as viruses and bacteria. Without inflammation as a physiological response, wounds would fester, and infections could become deadly. However, if the inflammatory process goes on for too long or if the inflammatory response occurs in places where it is not needed, it can become problematic. Chronic inflammation has been linked to certain diseases such as heart disease or stroke, and may also lead to autoimmune disorders, such as rheumatoid arthritis and lupus. As noted by Blaisdell et al, inflammation pervades virtually all forms of cancer even from the earliest stages of tumor development. Danger signals emanating from the tumor elicit local production of inflammatory cytokines and chemokines that subsequently draw inflammatory leukocytes into the neoplastic tissue. In general, inflammation is thought to nourish tumor growth and accelerate malignant progression. As noted by McDaniel et al, pathogenesis of chronic venous leg ulcers is related to the prolonged presence of high…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Inflammation and chronic inflammation, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Inflammation and chronic inflammation, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: